The Trauma INtramuscular Tranexamic Acid Clinical Trial

Phase 1/2 Completed 31 enrolled London School of Hygiene and Tropical Medicine Barts & The London NHS Trust · collab JP Moulton Charitable Foundation · collab St George's University Hospitals NHS Foundation Trust · collab University of Versailles · collab

NaSingle-groupOpen-labelOther

Summary

Intramuscular injection of tranexamic acid (TXA) would increase its use in situations where administration of intravenous drugs is difficult. The investigators aim to assess the population pharmacokinetics of intramuscular TXA in trauma patients. Primary endpoint: Serum TXA concentrations over time. Secondary endpoints: Local reactions at injection sites and adverse events

Timeline

Start: 2019-09-17
Primary completion: 2020-02-12
Completion: 2020-02-12

Publications

Grassin-Delyle S, Shakur-Still H, Picetti R, Frimley L, Jarman H, Davenport R, McGuinness W, Moss P, Pott J, Tai N, Lamy E, Urien S, Prowse D, Thayne A, Gilliam C, Pynn H, Roberts I. Pharmacokinetics of intramuscular tranexamic acid in bleeding trauma patients: a clinical trial. Br J Anaesth. 2021 Jan;126(1):201-209. doi: 10.1016/j.bja.2020.07.058. Epub 2020 Sep 30.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tranexamic Acid	Small molecule	1 g	Intramuscular

Indications

No indication recorded.